The Spanish dermocosmetic testing laboratory, focused on the substantiation of efficacy claims for active ingredients and end-product in vitro bioassays and clinical
tests in human volunteers, closed 2025 with an increase in turnover by 25.9 % compared to 2024. 298 projects were conducted throughout the whole year,
representing a 25% increase in activity year-on-year.
In 2025, studies on functional active ingredients accounted for 53% of total turnover, while evaluations of finished cosmetic products and oral nutraceuticals represented the remaining 47%. International clients generated 78% of total revenue, confirming Dermaclaim Lab’s strong global positioning, while 22% of turnover was derived from the national market.
As part of its sustainable growth strategy, Dermaclaim Lab inaugurated new facilities in September 2025. The expansion enabled the unification of laboratory and clinical departments within a single location, bringing together the company’s entire workforce of 17 employees. The new premises have increased operational capacity, enhanced access to a more diverse clinical volunteer database—including new skin ethnicities—and facilitated significant upgrades in both laboratory and clinical
equipment, contributing to further improvements in study quality and efficiency.
"The construction of the new facilities was a demanding process, as we started from a completely blank space in March 2025 and developed the infrastructure from scratch.
"Despite the challenges, the outcome has been highly satisfactory. Bringing our laboratory and clinical teams together under one roof will strengthen internal
collaboration, improve the working environment, and allow us to maintain the high reliability and scientific quality of our services while increasing capacity. Our priority now is to grow responsibly, in line with market demand, and continue delivering value to clients worldwide." - says David González, CEO of the company.
In parallel, the company has made substantial investments in state-of-the-art equipment to expand and reinforce its service portfolio. On the clinical side, new
acquisitions include two VISIA-CR (5th Generation) systems from Canfield; multiple Delfin Technologies devices such as VapoMeter, MoistureMeter SC, MoistureMeterEpiD, SebumScale, and ElastiMeter; and the C-Cube 3D imaging system from Pixience. Additionally, Dermaclaim Lab has duplicated its full range of Courage+Khazaka probes to ensure uninterrupted service in the event of technical issues. The laboratory department has also been fully equipped with in-house instrumentation, minimising reliance on external facilities, with the exception of highly specialised, high-cost technologies such as confocal microscopy, large-scale sequencing, and advanced chromatography systems.
Looking ahead, Dermaclaim Lab will participate as an exhibitor in 8 international industry events throughout 2026:
- PCHI China Hangzhou, March 18 th – 20 th (Booth 8J43)
- Incosmetics Global Paris, April 14 th – 16 th (Booth 1C79)
- Vitafoods Europe Barcelona, May 05th – 07th (Spanish Pav, ICEX)
- Suppliers’ Day New York, May 19 th – 20 th (Booth 1372)
- Incosmetics Latam Sao Paulo, September 23 rd – 24 th (Booth C92)
- Cosmetic 360 Paris, October 14 th – 15 th (Booth TBC)
- Cosmetorium Barcelona, October 21 st – 22 nd (Booth 112)
- Incosmetics Asia Bangkok, November 3 rd – 5 th (Booth AA68)
